BioNTech Reports Phase 2 Pumitamig Data in Advanced NSCLC
Pumitamig plus docetaxel produced a 36.7% confirmed ORR among 30 evaluable patients and median PFS of 6.9 months among 50 treated, with manageable safety.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.